Tarsus Retained Earnings from 2010 to 2024

TARS Stock

USD 46.40 0.18 0.39%

Tarsus Pharmaceuticals Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Tarsus Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2019-09-30

Previous Quarter

-313.7 M

Current Value

-337.1 M

Quarterly Volatility

108.8 M

Covid

Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 6.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 35.81, Dividend Yield of 0.0 or PTB Ratio of 3.17. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Tarsus Pharmaceuticals Correlation against competitors.

For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

Latest Tarsus Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Tarsus Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Tarsus Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tarsus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (244.66 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Tarsus Retained Earnings Regression Statistics

	Arithmetic Mean	(45,577,947)
	Coefficient Of Variation	(183.43)
	Mean Deviation	60,026,988
	Median	(1,364,000)
	Standard Deviation	83,604,715
	Sample Variance	6989.7T
	Range	243.3M
	R-Value	(0.74)
	Mean Square Error	3350.6T
	R-Squared	0.55
	Significance	0
	Slope	(13,925,630)
	Total Sum of Squares	97856.5T

Tarsus Retained Earnings History

	2024	-232.4 M
	2023	-244.7 M
	2022	-108.8 M
	2021	-46.7 M
	2020	-32.8 M
	2019	-6 M

Other Fundumenentals of Tarsus Pharmaceuticals

Retained Earnings Total Equity

Tarsus Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Short Term Debt	Capital Surpluse	Current Deferred Revenue	Long Term Debt	Intangible Assets
Total Assets		0.98	0.98	-0.87	-0.81	0.74	0.65	0.65	0.99	1.0	1.0	1.0	1.0	0.96	0.74	0.82	-0.49	0.61	-0.49
Total Stockholder Equity	0.98		1.0	-0.86	-0.75	0.68	0.58	0.49	1.0	0.98	0.98	0.98	0.98	0.96	0.79	0.75	-0.44	0.53	-0.44
Net Tangible Assets	0.98	1.0		-0.85	-0.75	0.68	0.58	0.51	1.0	0.98	0.98	0.98	0.98	0.96	0.76	0.78	-0.41	0.55	-0.41
Net Debt	-0.87	-0.86	-0.85		0.77	-0.77	-0.69	-0.56	-0.85	-0.87	-0.87	-0.87	-0.87	-0.89	-0.7	-0.58	0.64	-0.68	0.64
Retained Earnings	-0.81	-0.75	-0.75	0.77		-0.99	-0.97	-0.68	-0.78	-0.8	-0.81	-0.78	-0.81	-0.7	-0.49	-0.89	0.87	-0.93	0.87
Accounts Payable	0.74	0.68	0.68	-0.77	-0.99		0.99	0.66	0.71	0.74	0.75	0.71	0.75	0.64	0.44	0.83	-0.92	0.95	-0.92
Net Receivables	0.65	0.58	0.58	-0.69	-0.97	0.99		0.65	0.61	0.65	0.66	0.62	0.66	0.54	0.33	0.8	-0.94	0.97	-0.94
Total Liab	0.65	0.49	0.51	-0.56	-0.68	0.66	0.65		0.52	0.65	0.66	0.63	0.66	0.55	0.26	0.72	-0.49	0.66	-0.49
Net Invested Capital	0.99	1.0	1.0	-0.85	-0.78	0.71	0.61	0.52		0.99	0.98	0.98	0.98	0.96	0.77	0.8	-0.46	0.57	-0.46
Total Current Assets	1.0	0.98	0.98	-0.87	-0.8	0.74	0.65	0.65	0.99		1.0	1.0	1.0	0.96	0.75	0.82	-0.49	0.6	-0.49
Capital Stock	1.0	0.98	0.98	-0.87	-0.81	0.75	0.66	0.66	0.98	1.0		1.0	1.0	0.96	0.73	0.83	-0.49	0.62	-0.49
Net Working Capital	1.0	0.98	0.98	-0.87	-0.78	0.71	0.62	0.63	0.98	1.0	1.0		1.0	0.97	0.76	0.79	-0.47	0.57	-0.47
Common Stock	1.0	0.98	0.98	-0.87	-0.81	0.75	0.66	0.66	0.98	1.0	1.0	1.0		0.96	0.73	0.83	-0.49	0.62	-0.49
Property Plant Equipment	0.96	0.96	0.96	-0.89	-0.7	0.64	0.54	0.55	0.96	0.96	0.96	0.97	0.96		0.66	0.68	-0.41	0.51	-0.41
Short Term Debt	0.74	0.79	0.76	-0.7	-0.49	0.44	0.33	0.26	0.77	0.75	0.73	0.76	0.73	0.66		0.45	-0.29	0.25	-0.29
Capital Surpluse	0.82	0.75	0.78	-0.58	-0.89	0.83	0.8	0.72	0.8	0.82	0.83	0.79	0.83	0.68	0.45		-0.58	0.79	-0.58
Current Deferred Revenue	-0.49	-0.44	-0.41	0.64	0.87	-0.92	-0.94	-0.49	-0.46	-0.49	-0.49	-0.47	-0.49	-0.41	-0.29	-0.58		-0.88	1.0
Long Term Debt	0.61	0.53	0.55	-0.68	-0.93	0.95	0.97	0.66	0.57	0.6	0.62	0.57	0.62	0.51	0.25	0.79	-0.88		-0.88
Intangible Assets	-0.49	-0.44	-0.41	0.64	0.87	-0.92	-0.94	-0.49	-0.46	-0.49	-0.49	-0.47	-0.49	-0.41	-0.29	-0.58	1.0	-0.88

Click cells to compare fundamentals

About Tarsus Pharmaceuticals Financial Statements

Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-244.7 M	-232.4 M
Retained Earnings Total Equity	-97.9 M	-102.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC